Description
Illumina Bets on Multiomics & Proteomics – Is This the Future of Genomic Research?
Illumina Inc. delivered its second-quarter 2025 financial results, reporting revenue of $1.06 billion, which, despite a year-over-year decline, aligned with the high end of its guidance. Positively, the company significantly exceeded expectations with a non-GAAP operating margin of 23.8% and EPS of $1.19. These figures underline solid execution and underscore the robustness of its core business, particularly in clinical markets.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
